Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022
/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated...
Source: prnewswire.com